E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cerebral edema following Large Hemispheric Infarction |
Edema cerebral grave tras infarto hemisférico maligno |
|
E.1.1.1 | Medical condition in easily understood language |
Brain swelling after stroke |
Inflamación cerebral después del accidente cerebrovascular |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008107 |
E.1.2 | Term | Cerebral edema |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). |
El objetivo principal es determinar si BIIB093 mejora el resultado funcional en el día 90 según la medición de la Escala Rankin modificada (modified Rankin Scale, mRS) al compararlo con placebo en sujetos con IHM. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI. |
Los objetivos secundarios son determinar mejora la supervivencia general el día 90 en comparación con placebo,s i BIIB093 mejora el resultado funcional el día 90 en la mRS dicotomizada 0-4 frente a 5-6, en comparación con placebo, si BIIB093 reduce el cambio en la línea media a las 72 horas (o en el momento de la craneotomía descompresiva o de solo medidas paliativas, si se producen antes) en comparación con placebo y • Evaluar la seguridad y la tolerabilidad de BIIB093 en sujetos con IHM. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory
2.A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions
3. Screening National Institutes of Health Stroke Scale (NIHSS) >=10
4. Study treatment infusion within 10 hours after time of symptom onset, if known, or the time last known normal
5. For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI
NOTE: Other protocol defined Inclusion criteria may apply |
1. Diagnóstico clínico de accidente cerebrovascular isquémico agudo en el territorio de MCA.
2. Un infarto hemisférico maligno se define como: volumen de la lesión según resonancia magnética (RM) mediante imagen ponderada por difusión (IPD) de 80 a 300 cm3, o volumen de la lesión según perfusión por tomografía computarizada (PTC) de 80 a 300 cm3, o una puntuación de 1 a 5 del Programa de accidentes cerebrovasculares de Alberta (Alberta Stroke Program Early computed tomography Score, ASPECTS) con afectación de al menos 2 regiones corticales definidas.
3. NIHSS en la selección ≥10.
4. La infusión del tratamiento del fármaco del estudio se debe iniciar antes de que transcurran 10 horas desde el momento de la aparición de los síntomas, si se sabe, o el último momento conocido de normalidad.
5. Para los sujetos que reciben trombectomía, la inclusión en el estudio debe basarse en RM IPD posterior a la trombectomía.
Nota: Existen otros criterios de inclusión definidos por protocolo.
|
|
E.4 | Principal exclusion criteria |
1.Participant is likely to have supportive care withdrawn on the first day
2.Commitment to decompressive craniectomy (DC) prior to enrollment
3.Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome
NOTE: Other protocol defined Exclusion criteria may apply |
1. El sujeto es probable que se retire el tratamiento de apoyo el primer día.
2. Compromiso de craneotomía descompresiva (CD) antes de la inscripción.
3. Indicios de infarto concurrente en el hemisferio contralateral lo suficientemente grave como para afectar a los resultados funcionales.
Nota: Existen otros criterios de exclusión definidos por protocolo.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of Participants with Improvement in Functional Outcome at Day 90 Assessed via the Modified Rankin Scale (mRS) |
Proporción de sujetos con mejoría en el resultado funcional en el día 90 evaluada según la medición de la Escala Rankin modificada (modified Rankin Scale, mRS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline up to Day 90 |
Línea media hasta el día 90 |
|
E.5.2 | Secondary end point(s) |
1.Time to All-Cause Death [ Time Frame: Baseline up to Day 90 ]
2.Proportion of Participants who achieved mRS 0-4 at Day 90 [Time Frame: Baseline up to Day 90]
3.Reduction in Midline Shift at 72 Hours [ Time Frame: Baseline up to 72 Hours]
4.Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to Day 90] |
1. Tiempo transcurrido hasta la muerte por cualquier causa (desde Visita Basal hasta el día 90).
2. Proporción de sujetos que lograron una mRS de 0-4 el día 90 (desde Visita Basal hasta el día 90).
3. Cambio en la línea media a las 72 horas (desde Visita Basal hasta las 72 horas).
4. La incidencia de acontecimientos adversos, acontecimientos adversos graves (AAG) (desde Visita Basal hasta el día 90). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
#’s 1, 2 & 4 (Baseline up to Day 90)
#3 (Baseline up to 72 hours) |
# 's 1, 2 y 4 (Línea media hasta el día 90)
# 3 (Línea media a las 72 horas) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 68 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Brazil |
Canada |
Czech Republic |
Denmark |
Finland |
France |
Germany |
Hungary |
Israel |
Italy |
Japan |
Korea, Republic of |
Mexico |
Portugal |
Russian Federation |
Spain |
Switzerland |
Taiwan |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |